ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly cash paid for IPR&D and development milestones ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Cash Flows
Latest, Q2 2026
3,282
Period ended Jun 30, 2026
Change on a year earlier
+2,967.3%
107 in Q2 2025
History
17 quarters
Since Q1 2016
Sources
12
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cash paid for IPR&D and development milestones ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,282 | +2,967.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 204 | -88.4% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 424 | +68.5% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 720 | -74.5% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 107 | -39.9% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,757 | +1,720.7% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 251 | -56.7% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,820 | -7.0% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 178 | +81.4% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 96.5 | -58.9% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 580 | +320.6% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2023 | Sep 30, 2023 | 3,031 | – | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 98.1 | – | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 235 | – | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 138 | – | Form 10-K (filed 2025-02-19) ↗ |
| Q2 2016 | Jun 30, 2016 | 0 | – | Form 10-Q (filed 2016-07-28) ↗ |
| Q1 2016 | Mar 31, 2016 | 0 | – | Form 10-Q (filed 2016-04-29) ↗ |
Cite this data
StockData. (2026). Eli Lilly Cash paid for IPR&D and development milestones ($M) ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/iprd_cash_paid
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.